News

Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement

Valneva is a biotech company developing and commercializing vaccines for...

HOOKIPA and DarwinHealth Enter into a Research Collaboration and License...

DarwinHealth is a precision-focused cancer medicine company, utilizing...

HOOKIPA Receives 2018 Lifestars Award for Best Deal of the Year

On June 5, HOOKIPA announced a research collaboration and licensing agreement...

HOOKIPA Appoints Julie O’Neill as a Non-Executive Director

A business professional with more than two decades of executive experience in...

Hookipa Appoints Dr. Christoph Lengauer to its Board of Directors as a...

Dr. Lengauer has an outstanding track-record in cancer drug discovery,...

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop...

Hookipa and Gilead will jointly develop therapeutics against HIV and Hepatitis...

New Insights into Hookipa’s TheraT® Replicating Viral Vector Platform...

TheraT®-induced CD8+ T cells are resistant to select checkpoint inhibitors,...

Hookipa Biotech to Present New Phase 1 Data for its Cytomegalovirus Vaccine,...

Vaccine has a good safety profile and elicits strong humoral and cellular...

Hookipa Biotech To Present at the Cowen and Company 38th Annual Healthcare...

The presentation will be held by Joern Aldag, CEO of Hookipa Biotech. He will...

Hookipa Biotech to Attend the LEERINK Partners 7th Annual Global Healthcare...

Mr. Aldag and Dr. Matushansky will participate in a series of one-on-one...

Hookipa Biotech to Present at 36th Annual J.P. Morgan Healthcare Conference...

Mr. Aldag will provide an overview of the Company´s strategy as well as an...

Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C...

The round was led by an undisclosed blue chip U.S. public investment fund...

Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors

Dr. Jan van de Winkel is currently President and Chief Executive Officer of...

Hookipa Biotech Announces Nature Communications Publication Showing TheraT®...

“This key research data is the first publication on Hookipa’s platform...

Hookipa Biotech presents positive data from Phase 1 first-in-human trial of...

Vaccine was safe and elicited a potent immune response. Cytomegalovirus (CMV)...

Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech

Reinhard Kandera has more than 20 years of professional experience in the...

Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa...

Dr. Matushansky joins Hookipa from Daiichi Sankyo, where he was the Global...

Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology...

Cytomegalovirus (CMV) infection is the leading cause of congenital infection...